Trial Profile

A Multi-Center, Open-Label, Phase 2 Study to Evaluate Safety and Efficacy of U3-1402 in Subjects With Advanced or Metastatic Colorectal Cancer (CRC)

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 21 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Patritumab Deruxtecan (Primary)
Indications Adenocarcinoma; Colon cancer; Colorectal cancer; Rectal cancer
Focus Therapeutic Use
Sponsors Daiichi Sankyo Inc

Most Recent Events

09 Mar 2022 This trial has been completed in Poland (End Date: 28 Jan 2022), according to European Clinical Trials Database record.
11 Nov 2021 Status changed from recruiting to discontinued.
03 Jul 2021 The enrollment for Part 1 is now closed. Forty patients were enrolled in Part 1, as per trial design presented at the 23rd World Congress on Gastrointestinal Cancer.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com